Lv11
10 积分 2023-03-08 加入
SGLT2 inhibition and three urological cancers: Up‐to‐date results
5小时前
已完结
Congestive heart failure with vascular endothelial growth factor receptor tyrosine kinase inhibitors
4个月前
已完结
Conquests and perspectives of cardio-oncology in the field of tumor angiogenesis-targeting tyrosine kinase inhibitor-based therapy
4个月前
已完结
Cardiovascular Toxicities of Antiangiogenic Tyrosine Kinase Inhibitors: A Retrospective, Pharmacovigilance Study
4个月前
已关闭
The Diagnosis and Management of Cardiovascular Disease in Cancer Patients
4个月前
已完结
Cardiovascular Toxic Effects of Targeted Cancer Therapies
4个月前
已完结
Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes
4个月前
已完结
CARDIOVASCULAR SIDE EFFECTS OF TYROSINE KINASE INHIBITORS USED FOR CANCER THERAPY: ANALYSIS OF SAFETY REPORTS FROM THE WORLD HEALTH ORGANIZATION VIGIBASE DATASETS
4个月前
已完结
An update on the conquests and perspectives of cardio-oncology in the field of tumor angiogenesis-targeting TKI-based therapy
4个月前
已完结
Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial
6个月前
已完结
皖公网安备34019202002308
